🔴 Aquestive Therapeutics is trading 9.1% down in pre-market with no company-specific explanation identified

Aquestive Therapeutics is trading 9.1% lower at $3.71 in pre-market on October 22, with no company-specific announcement identified to explain the decline; broader market weakness may be adding pressure.

• Latest company news found was the October 15 FDA acceptance of Anaphylm’s NDA resubmission, with a March 16, 2027 PDUFA date.
• Broader markets are sharply lower pre-market, while the biotech ETF is reported higher; no volume or activity data was provided to confirm trading intensity.